225 related articles for article (PubMed ID: 24504766)
1. Cabergoline treatment in acromegaly: cons.
Kasuki L; Vieira Neto L; Gadelha MR
Endocrine; 2014 Jun; 46(2):220-5. PubMed ID: 24504766
[TBL] [Abstract][Full Text] [Related]
2. Cabergoline treatment in acromegaly: pros.
Marazuela M; Ramos-Leví A; Sampedro-Núñez M; Bernabeu I
Endocrine; 2014 Jun; 46(2):215-9. PubMed ID: 24532103
[TBL] [Abstract][Full Text] [Related]
3. Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial.
Higham CE; Atkinson AB; Aylwin S; Bidlingmaier M; Drake WM; Lewis A; Martin NM; Moyes V; Newell-Price J; Trainer PJ
J Clin Endocrinol Metab; 2012 Apr; 97(4):1187-93. PubMed ID: 22278424
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline in acromegaly.
Kuhn E; Chanson P
Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
[TBL] [Abstract][Full Text] [Related]
5. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy.
Ferone D; Pivonello R; Lastoria S; Faggiano A; Del Basso de Caro ML; Cappabianca P; Lombardi G; Colao A
Clin Endocrinol (Oxf); 2001 Apr; 54(4):469-77. PubMed ID: 11318782
[TBL] [Abstract][Full Text] [Related]
6. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study.
Puig-Domingo M; Soto A; Venegas E; Vilchez R; Blanco C; Cordido F; Lucas T; Marazuela M; Casany R; Cuatrecasas G; Fajardo C; Gálvez MÁ; Maraver S; Martín T; Romero E; Paja M; Picó A; Bernabeu I; Resmini E;
Endocrinol Nutr; 2016 Oct; 63(8):397-408. PubMed ID: 27448708
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological approach to the treatment of acromegaly.
Ezzat S
Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
[TBL] [Abstract][Full Text] [Related]
8. Short- and long-term efficacy of combined cabergoline and octreotide treatment in controlling igf-I levels in acromegaly.
Mattar P; Alves Martins MR; Abucham J
Neuroendocrinology; 2010; 92(2):120-7. PubMed ID: 20802256
[TBL] [Abstract][Full Text] [Related]
9. Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients.
Gatta B; Hau DH; Catargi B; Roger P; Tabarin A
Clin Endocrinol (Oxf); 2005 Oct; 63(4):477-8. PubMed ID: 16181243
[No Abstract] [Full Text] [Related]
10. The efficacy of medical treatment in patients with acromegaly in clinical practice.
Lee SY; Kim JH; Lee JH; Kim YH; Cha HJ; Kim SW; Paek SH; Shin CS
Endocr J; 2018 Jan; 65(1):33-41. PubMed ID: 28931779
[TBL] [Abstract][Full Text] [Related]
11. Optimizing medical therapy of acromegaly: beneficial effects of cabergoline in patients uncontrolled with long-acting release octreotide.
Jallad RS; Bronstein MD
Neuroendocrinology; 2009; 90(1):82-92. PubMed ID: 19439914
[TBL] [Abstract][Full Text] [Related]
12. The role of combination medical therapy in acromegaly: hope for the nonresponsive patient.
Fleseriu M
Curr Opin Endocrinol Diabetes Obes; 2013 Aug; 20(4):321-9. PubMed ID: 23807604
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status.
Cozzi R; Attanasio R; Lodrini S; Lasio G
Clin Endocrinol (Oxf); 2004 Aug; 61(2):209-15. PubMed ID: 15272916
[TBL] [Abstract][Full Text] [Related]
14. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
15. The role of primary pharmacological therapy in acromegaly.
Espinosa de los Monteros AL; Carrasco CA; Albarrán AA; Gadelha M; Abreu A; Mercado M
Pituitary; 2014 Jan; 17 Suppl 1(Suppl 1):S4-10. PubMed ID: 24166706
[TBL] [Abstract][Full Text] [Related]
16. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
Cozzi R; Attanasio R; Barausse M; Dallabonzana D; Orlandi P; Da Re N; Branca V; Oppizzi G; Gelli D
Eur J Endocrinol; 1998 Nov; 139(5):516-21. PubMed ID: 9849816
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of octreotide, cabergoline and a combination of both drugs on GH secretion in acromegalic patients.
Minniti G; Jaffrain-Rea ML; Baldelli R; Ferretti E; Caracciolo B; Bultrini A; Gulino A; Tamburrano G
Clin Ter; 1997 Dec; 148(12):601-7. PubMed ID: 9528195
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological management of acromegaly: a current perspective.
Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of high-dose long-acting repeatable octreotide as monotherapy or in combination with pegvisomant or cabergoline in patients with acromegaly not adequately controlled by conventional regimens: results of an open-label, multicentre study.
Colao A; Zgliczyński W; Komorowski J; Kos-Kudła B; Tabarin A; Kerlan V; Minuto FM; Scaroni C; Bolanowski M
Endokrynol Pol; 2019; 70(4):305-312. PubMed ID: 31274183
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and treatment outcomes of pegvisomant in Japanese patients with acromegaly: results from the post-marketing surveillance.
Yamaguchi H; Shimatsu A; Okayama A; Sato T
Endocr J; 2020 Feb; 67(2):201-210. PubMed ID: 31723069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]